© 2015 ACIN. The current first line treatment for chronic hepatitis B virus is with entecavir and tenofovir. However, there are few data regarding the results obtained from these treatments in clinical practice. Objective To assess viral response and safety of treatment with entecavir and tenofovir in a 5-year follow-up. Material and methods Observational study on patients with chronic hepatitis B virus who began treatment with tenofovir or entecavir between January 2008 and December 2012. Results Seventy patients were included; 42 (60%) were treated with entecavir and 28 (40%) with tenofovir. Of these, 75.7% were men, with an average age of 53 (SD ± 14) years, and most were white (70%). A liver biopsy was performed on 46 patients (F0 8.7%; F1 6.5%; F2 26.1%; F3 43.5% and F4 15.2%). Of all the patients, 51.4% were treatment naïve, and of the group of previously treated patients, 17.6% had received interferon; 26.4% had received interferon followed by one or more analogues; and 55.8% had received other nucleoside or nucleotide analogues. The time of follow-up was 36 (SD ± 12) months. The average initial DNA was 31,570,006 UI/mL (range 24-1,100,000,000 UI/mL). All except 3 presented undetectable DNA after one year of treatment. Ten patients were HBeAg-positive at the beginning of the treatment and 2 seroconverted. At the beginning of the treatment, creatinine was 0.9 (SD ± 0.3) mg/dL and the estimated glomerular filtration rate (eGFR) was 93.92 ml/min/1.73 m2 (DE 21.92); both keeping stable after a year of treatment (creatinine levels 0.93 [SD ± 0.27] mg/dL, eGFR 91.7392 [SD ± 21.38] ml/min/1.73 m2). Conclusions Entecavir and tenofovir are safe and effective in clinical practice for the treatment of chronic hepatitis B virus, both in treatment-naïve patients and in those previously treated.
- Chronic hepatitis
- Hepatitis B
- Oral antiviral agents
- Tenofovir, Entecavir
Horta, D., Fernandez-Atutxa, A., Miquel, M., Vergara, M., Casas, M., & Sánchez-Delgado, J. (2016). Results in clinical practice of treatment of chronic hepatitis b virus with tenofovir and entecavir. Infectio, 20(3), 123-129. https://doi.org/10.1016/j.infect.2015.06.001